The Pharmacare Act aims to establish a national framework for universal pharmacare in Canada to make prescription drugs more accessible and affordable. It emphasizes collaboration with various stakeholders to develop a national drug formulary and a bulk purchasing strategy intended to lower costs and improve public health outcomes.
This legislation could significantly impact Canadians needing prescription medications, including individuals with chronic conditions like diabetes and those requiring contraception. It promotes better access to medication without out-of-pocket expenses for many patients. However, concerns remain that regional variations in healthcare needs might not be adequately addressed, leaving some communities at a disadvantage.
Funding for the Pharmacare Act will come from the Consolidated Revenue Fund, but there are doubts about long-term financial sustainability. Critics worry about the potential increase in government spending and the associated administrative costs stemming from establishing a national formulary and bulk purchasing agreement. The financial implications may lead to higher taxes or reallocations from other essential services if government budgets become strained.
Supporters of the Act see it as a critical step towards equitable healthcare, ensuring that all Canadians can afford necessary medications without financial burden. They believe that through collective purchasing power, drug prices can be negotiated down, ultimately benefiting public health and preventing further healthcare costs related to untreated conditions.
Critics express skepticism about the sustainability of the funding model required to support such an ambitious pharmacare system. There are fears that implementation delays and potential bureaucratic hurdles may arise, which could limit immediate access to necessary medications. Additionally, concerns linger regarding whether a standardized approach may not cater to the unique health needs of different provinces and territories, leading to inefficiencies in healthcare delivery.
That the motion be amended by deleting all the words after the word "That" and substituting the following: “the House decline to give second reading to Bill C-64, An Act respecting pharmacare, since the bill does nothing to address the health care crisis and will instead offer Canadians an inferior pharmacare plan that covers less, costs more, and builds up a massive new bureaucracy that Canadians can’t afford.”.
That the bill be now read a third time and do pass.
That the bill be now read a second time and referred to the Standing Committee on Health.
The information is not available at this time.
That Bill C-64, An Act respecting pharmacare, as amended, be concurred in at report stage.
That in relation to Bill C-64, An Act respecting pharmacare, not more than five further hours shall be allotted to the consideration at second reading stage of the bill; and That, at the expiry of the five hours provided for consideration at second reading stage of the said bill, any proceedings before the House shall be interrupted, if required for the purpose of this order, and, in turn, every question necessary for the disposal of the said stage of the bill shall be put forthwith and successively, without further debate or amendment.